These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29306674)

  • 1. A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failure.
    Taussky D; Bedwani S; Meissner N; Bahary JP; Lambert C; Barkati M; Beauchemin MC; Ménard C; Delouya G
    Brachytherapy; 2018; 17(2):277-282. PubMed ID: 29306674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
    Morris WJ; Pickles T; Keyes M
    Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
    Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D
    BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of external beam radiotherapy versus permanent seed brachytherapy as monotherapy for intermediate-risk prostate cancer - a single center Canadian experience.
    Delouya G; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Taussky D
    Can J Urol; 2017 Jun; 24(3):8822-8826. PubMed ID: 28646937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.
    Taussky D; Lambert C; Meissner N; Bahary JP; Delouya G
    Brachytherapy; 2018; 17(5):794-798. PubMed ID: 30153914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy.
    Patel N; Souhami L; Mansure JJ; Duclos M; Aprikian A; Faria S; David M; Cury FL
    Brachytherapy; 2014; 13(5):450-5. PubMed ID: 25023396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the Cancer of the Prostate Risk Assessment to predict for biochemical failure after external beam radiotherapy or prostate seed brachytherapy.
    Delouya G; Krishnan V; Bahary JP; Larrivée S; Taussky D
    Urology; 2014 Sep; 84(3):629-33. PubMed ID: 25168545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer.
    Fukuokaya W; Kim S; Natsuyama T; Matsuzaki K; Shiomi H; Kitoh H; Utsumi N; Kurosaki H; Inoue M; Akakura K
    Int J Clin Oncol; 2018 Apr; 23(2):361-367. PubMed ID: 29151227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
    Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
    Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
    Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
    Nishimura S; Ohashi T; Momma T; Sakayori M; Eriguchi T; Tanaka T; Yamashita S; Kosaka T; Oya M; Shigematsu N
    Cancer Med; 2018 May; 7(5):1794-1801. PubMed ID: 29577651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer.
    Luo Y; Li M; Qi H; Zhao J; Han Y; Lin Y; Hou Z; Jiang Y
    World J Surg Oncol; 2018 Jun; 16(1):107. PubMed ID: 29890979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
    Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
    Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
    Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.
    Ahmed KA; Davis BJ; Mynderse LA; Slezak JM; Bergstralh EJ; Wilson TM; Choo CR
    Radiat Oncol; 2014 Jul; 9():171. PubMed ID: 25074478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer.
    Delouya G; Kaufman G; Sylvestre MP; Nguyen TV; Bahary JP; Taussky D; Després P
    Cancer Epidemiol; 2012 Apr; 36(2):e137-41. PubMed ID: 22094327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.